title: Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.
authors.affiliation: Department of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. pbeniwal-patel@uwhealth.org.
authors.forename: Poonam
authors.initials: P
authors.lastname: Beniwal-Patel
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison, WI, USA.
authors.forename: Kristina
authors.initials: K
authors.lastname: Matkowskyj
authors.affiliation: Department of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
authors.forename: Freddy
authors.initials: F
authors.lastname: Caldera
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D003092:Colitis / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D003113:Colonoscopy; D004351:Drug Resistance; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab; D000069285:Infliximab